| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GLYC | Common Stock | Purchase | $2.16M | +1M | +15.21% | $2.16 | 7.57M | Feb 15, 2023 | Direct | F1, F2, F3 |
| transaction | GLYC | Common Stock | Purchase | $531K | +315K | +4.16% | $1.68 | 7.89M | Feb 16, 2023 | Direct | F1, F2, F4 |
| transaction | GLYC | Common Stock | Purchase | $341K | +200K | +2.54% | $1.71 | 8.09M | Feb 17, 2023 | Direct | F1, F2, F5 |
| Id | Content |
|---|---|
| F1 | The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group, S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). |
| F2 | (Continued from Footnote 1) Mr. Amaury Wittouck is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.75 to $2.50 per share, inclusive. The Reporting Persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.47 to $1.80 per share, inclusive. The Reporting Persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.64 to $1.77 per share, inclusive. The Reporting Persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |